加拿大多伦多一家儿科三级转诊医院 1-11 岁免疫力低下儿童在接种疫苗前感染 SARS-CoV-2 的情况。

IF 2.4 3区医学 Q2 HEMATOLOGY

Pediatric Blood & Cancer Pub Date : 2024-10-04 DOI:10.1002/pbc.31365

Dara Petel, Mohsin Ali, James Wright, Aaron Campigotto, Michelle Science, Sumit Gupta, Shelly Bolotin

{"title":"加拿大多伦多一家儿科三级转诊医院 1-11 岁免疫力低下儿童在接种疫苗前感染 SARS-CoV-2 的情况。","authors":"Dara Petel, Mohsin Ali, James Wright, Aaron Campigotto, Michelle Science, Sumit Gupta, Shelly Bolotin","doi":"10.1002/pbc.31365","DOIUrl":null,"url":null,"abstract":"<p>SARS-CoV-2 seroprevalence reflects the efficacy of pandemic infection prevention and control measures. We performed anti-spike IgG serological testing on residual sera of children 1–11 years old at a tertiary care referral center between October and November 2021. Immunocompromised patients had the highest SARS-CoV-2 seroprevalence, at 40.5%, compared to 19.3% in non-immunocompromised patients. Targeted infection prevention and public health interventions are warranted for pediatric immunocompromised patients in future pandemics.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"71 12","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Burden of SARS-CoV-2 infection prior to vaccine eligibility among immunocompromised children aged 1–11 years at a pediatric tertiary referral hospital in Toronto, Canada\",\"authors\":\"Dara Petel, Mohsin Ali, James Wright, Aaron Campigotto, Michelle Science, Sumit Gupta, Shelly Bolotin\",\"doi\":\"10.1002/pbc.31365\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>SARS-CoV-2 seroprevalence reflects the efficacy of pandemic infection prevention and control measures. We performed anti-spike IgG serological testing on residual sera of children 1–11 years old at a tertiary care referral center between October and November 2021. Immunocompromised patients had the highest SARS-CoV-2 seroprevalence, at 40.5%, compared to 19.3% in non-immunocompromised patients. Targeted infection prevention and public health interventions are warranted for pediatric immunocompromised patients in future pandemics.</p>\",\"PeriodicalId\":19822,\"journal\":{\"name\":\"Pediatric Blood & Cancer\",\"volume\":\"71 12\",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Blood & Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pbc.31365\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Blood & Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pbc.31365","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

SARS-CoV-2 血清流行率反映了大流行感染预防和控制措施的效果。2021 年 10 月至 11 月期间，我们在一家三级医疗转诊中心对 1-11 岁儿童的残留血清进行了抗穗 IgG 血清学检测。免疫力低下的患者SARS-CoV-2血清阳性率最高，为40.5%，而非免疫力低下的患者为19.3%。在未来的大流行中，有必要对儿科免疫力低下的患者采取有针对性的感染预防和公共卫生干预措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Burden of SARS-CoV-2 infection prior to vaccine eligibility among immunocompromised children aged 1–11 years at a pediatric tertiary referral hospital in Toronto, Canada

SARS-CoV-2 seroprevalence reflects the efficacy of pandemic infection prevention and control measures. We performed anti-spike IgG serological testing on residual sera of children 1–11 years old at a tertiary care referral center between October and November 2021. Immunocompromised patients had the highest SARS-CoV-2 seroprevalence, at 40.5%, compared to 19.3% in non-immunocompromised patients. Targeted infection prevention and public health interventions are warranted for pediatric immunocompromised patients in future pandemics.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pediatric Blood & Cancer 医学-小儿科

CiteScore

4.90

自引率

9.40%

发文量

546

审稿时长

1.5 months

期刊介绍： Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.